Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers predicting anti-TNF response in pediatric and adult IBD
NL-OMON39856Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab and adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis, sponsored by Erasmus MC. Started Nov 2013; status: active, not recruiting.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON39856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39856.